Front Row Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Front Row Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-106	Closed	-$12K	–	972
2022 Q4	$12K	Buy	106 +11	+12%	+$914	0.01%	471
2022 Q3	$6K	Sell	95 -7	-7%	-$489	﹤0.01%	630
2022 Q2	$8K	Buy	102 +12	+13%	+$1.14K	﹤0.01%	568
2022 Q1	$9K	Hold	90	–	–	﹤0.01%	580
2021 Q4	$10K	Sell	90 -5	-5%	-$545	﹤0.01%	585
2021 Q3	$10K	Hold	95	–	–	﹤0.01%	576
2021 Q2	$10K	Sell	95 -1	-1%	-$92	﹤0.01%	577
2021 Q1	$9K	Buy	96 +30	+45%	+$2.53K	﹤0.01%	583
2020 Q4	$5K	Buy	+66	New	+$4.91K	﹤0.01%	706
2019 Q3	–	Sell	-211	Closed	-$5K	–	1062
2019 Q2	$5K	Hold	211	–	–	﹤0.01%	609
2019 Q1	$6K	Hold	211	–	–	﹤0.01%	557
2018 Q4	$4K	Hold	211	–	–	﹤0.01%	630
2018 Q3	$4	Hold	211	–	–	﹤0.01%	650
2018 Q2	$4	Buy	+211	New	+$3.22K	﹤0.01%	715

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Front Row Advisors's HZNP Position: Q1 2023 in Review

Front Row Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 106 shares — an estimated $12K sold.

Front Row Advisors first reported a position in HZNP in Q2 2018 and held it in 14 quarters. The position peaked at $12K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Front Row Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Front Row Advisors sold 106 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $12K.
Front Row Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and held it in 14 quarters.
Front Row Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Front Row Advisors's 13F filing for Q1 2023, filed 15 May 2023.